{"name":"Knight Therapeutics","slug":"knight","ticker":"GUD.TO","exchange":"TSX","domain":"knighttx.com","description":"Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange, with a market capitalization of $1.02 billion as of August 2019.","hq":"Montreal, Quebec, Canada","founded":2010,"employees":"830","ceo":"Samira Sakhia","sector":"Specialty Pharma / Licensing & Distribution","stockPrice":7.62,"stockChange":-0.03,"stockChangePercent":-0.39,"marketCap":"$757M","metrics":{"revenue":450088000,"revenueGrowth":37.4,"grossMargin":44.5,"rdSpend":0,"netIncome":-5374000,"cash":114229000,"dividendYield":0,"peRatio":28.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Xermelo patent cliff ($143.8M at risk)","drug":"Xermelo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Knight Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Knight Therapeutics reported its financial results for the fourth quarter and full year 2023, with revenue of $143.8 million and a net loss of $13.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-31","type":"deal","headline":"Knight Therapeutics Announces Agreement to Acquire Rights to Xermelo in Canada","summary":"Knight Therapeutics announced an agreement to acquire the rights to Xermelo, a treatment for carcinoid syndrome diarrhea, in Canada from NPS Pharmaceuticals.","drugName":"","sentiment":"positive"},{"date":"2022-11-15","type":"regulatory","headline":"Health Canada Approves Xermelo for the Treatment of Carcinoid Syndrome Diarrhea","summary":"Health Canada approved Xermelo for the treatment of carcinoid syndrome diarrhea, marking a significant milestone for Knight Therapeutics.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1Zc0VPTzVURTNaREZOSGljMkdVTXNHYnhHT0dzWF9FSXJIU1k4X3Z2RWtrVEtsWGtyN3VFUFVvR2VqQVdhczQxTXl3MWFtWXdQQmlhMw?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Cipher Pharmaceuticals Inc. (CPH.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Cipher Pharmaceuticals Inc. (CPH.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOanVrMG56VzZoSlZnQS1maWFxdlR5OEQxQkc0Vk9EWU5aNGxXNmNQNEJTRkpsakJTWW9ST2I3N0NEenBXdklhR3k1RjFNV0hFcnpscUw2SFZTMUdhS0QyVVB2LXBTRmxkTWpTVWM0eXNrU2tWdVpRS0I2N2E0QlB2QnhsZ3MzM3F6MkNlQ0ZtTi0wS0QzX2tSR3RLOUdGQnNa?oc=5","date":"2026-03-23","type":"pipeline","source":"Yahoo Finance","summary":"Knight Amends Normal Course Issuer Bid - Yahoo Finance","headline":"Knight Amends Normal Course Issuer Bid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQYVVjTzU0MWVuWHlROU55Rl9xR1ItWXZ0cVhlSGN4R2ZTSnVXNVRWRmpobk4tSlBDX3V6Y05mdmppUW9QaV9PQ3MtMmIxSHhUMS1HOFZjakZndWw4UDVWOGpxV0VoQVNNcDMzNmZKaUNMaE03amxMQlg1Vmw0VnBGNWVzck00MmYybGpQdm42VXltR3VXOEpHTzhmX0ZLVGNu?oc=5","date":"2026-03-17","type":"regulatory","source":"Yahoo Finance","summary":"Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico - Yahoo Finance","headline":"Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Ar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNX1YzdUJmcWtXYkpEZmtoeHVWNGxTc1JqVmt6bkJYSDM1aXNCdGs2c0RGeTZxQnRMektXd0dkdVd3OWV1cXQzWExzTjRSdEpTZy1ZNFdiU1dTN2JKT29PYWt2cGs0eW1Ga0NYd2lNMjZwRHV0SGtxcUZtb0VCTWE4S29SeEt2aTVQSTRHRTZnb09scmpkOThjcl9FQQ?oc=5","date":"2026-03-17","type":"regulatory","source":"Yahoo Finance","summary":"Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil - Yahoo Finance","headline":"Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOZVczYUtjUHNqd3dWNjFPUW9nNXpkcEhlTV9fR21XSTN6ZmZScW5uNnE1eklrSzZaZjE1blp3MGFYWWpCN05nSm5ITUg1cjNnYVFoZHV0bFBTZ3g1NGJ0bFViY0N4R1hVTGZEQXR6eXhzR3JoVzdyYlZCR2ltTDVMY3dpWFdUS2tJQmJfWmtpaHBUU2M?oc=5","date":"2025-10-30","type":"pipeline","source":"Yahoo Finance","summary":"Knight Therapeutics Announces Launch of JORNAY PM™ in Canada - Yahoo Finance","headline":"Knight Therapeutics Announces Launch of JORNAY PM™ in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNdDgxRGxZTU9pSHQtdUdkRU91SUlEbVgxMGZ6WkNuNlJOeEtjd1h6Yi1xSjZXaldjaFFlQ0V2ZXduVjFNRndHU1JQc2xXS21GUlQ1Z2xVbmZ4aEtUNkRjYWJ2UXNDVEdXVHoyejFXVkZYVmJFUUNBWGlEZFBJT0RYRVZIMXFiUTlhSXpsZmJCQi1xeG1sQVBz?oc=5","date":"2025-10-07","type":"pipeline","source":"Yahoo Finance","summary":"Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada - Yahoo Finance","headline":"Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNUE1WR3c3NEh2SE5xSEhJZ2hxd3h6cW1HTVdHMVd1Mjhua1pJeU5SVzRlak1zY2Q1OGIzSzNNOHVCSXgtS3Fzb0d1X1Jtc0t5Nlp1cHlqU0Q5aWVEQ25TcmYwMV9rN3gwSlM1QXh2MnRIcFRzM2VtQjB6Tk0yN0ZFc1R5bktILS1SazNkLWNkTmJ6T3F1UXhfZXVR?oc=5","date":"2025-10-07","type":"pipeline","source":"Yahoo Finance","summary":"Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada - Yahoo Finance","headline":"Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPdmR0ZUd4OThqWlh0MDdqUHotbm9LMk5ka1M3bzYtSlI5NkYzZFBuU19ZZGNMb2x6azlpYUg2b3Q5eGpPNnRTNEltbTcwTjJqRE8wMzdJSUswNGxZa3VZZGlYTVRiVXpvZlpNanFhUURCclY3dkVWUDVjaG9KVEJXcGpMczh3ajQ5T3dZZ3ZHVHlzMnI3ZWFhQ1dCWWdUZw?oc=5","date":"2025-08-05","type":"regulatory","source":"Yahoo Finance","summary":"Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico - Yahoo Finance","headline":"Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Me","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPR25TLVFKVlo5LWhVdDZTVnpHZkppbXU5NkwyQkRPSkNzcWJucHhCdDVKbWFKNk42ZUNOQ2FWaUlRb3RqQmt4Tk1YWFp5ZUlKZDVqNmp2SHVPRzZpVVVpS2FDZk5NaWp0TzZuTHU0bmxRbXI3QVM4VXlabGF5TGJGUHFHVFJPNTlmVjdYWUQxQ1g?oc=5","date":"2025-07-18","type":"pipeline","source":"Yahoo Finance","summary":"Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada - Yahoo Finance","headline":"Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQZWlVVUVzYXlPbVVUT2E5bGdubWtyXy1tcm5sVFY5STNOeWxyMUlXcUIzdXdPWmFzNFFIcU5DWWlmZ2dLU0hMU0hKZUpvWHVLQzQzM1RRc3VUVDJGMm9sSjBNeTBuc0JVNDVNNUMwaDJyaXZGZ21hMHVkRGQ4anZTRDZwNTYtMlZqdDVsREhmTmpiOXBZN0xlNUdn?oc=5","date":"2025-06-17","type":"pipeline","source":"Yahoo Finance","summary":"Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin - Yahoo Finance","headline":"Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5zZUJWd3lPajUwdXQ2TmpvakdLbzRoMW9FaUt0R29HMEF5VW9lZDRHa3YyMU5IRTZMX09uOTZfU0ctMzlrLWlCbnVSVmVjNGpRMzJQY1VMMA?oc=5","date":"2021-10-08","type":"pipeline","source":"TradingView","summary":"GUD Stock Price and Chart — TSX:GUD - TradingView","headline":"GUD Stock Price and Chart — TSX:GUD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5VdzRrSzJFX2VRVVdJVlpQYlo5RzFVU3VQeUx1bWZhYXRmcFhaTG1nMi1UbnhTQThvR1Z1YzRNd2UzbXBRcWNyRlJ5V1IwblJBZWVVaw?oc=5","date":"2016-08-12","type":"pipeline","source":"MarketBeat","summary":"Knight Therapeutics (GUD) Stock Price, News & Analysis $GUD - MarketBeat","headline":"Knight Therapeutics (GUD) Stock Price, News & Analysis $GUD","sentiment":"neutral"}],"patents":[{"drugName":"Xermelo","drugSlug":"telotristat-etiprate","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"Canada","annualRevenue":143800000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Aurora Cannabis","Canopy Growth","Pharmascience"],"therapeuticFocus":["Oncology","Rare Diseases"],"financials":null,"yahoo":{"currentPrice":7.62,"previousClose":7.65,"fiftyTwoWeekHigh":7.74,"fiftyTwoWeekLow":5.43,"fiftyTwoWeekRange":"5.43 - 7.74","fiftyDayAverage":6.36,"twoHundredDayAverage":6.14,"beta":0.04,"enterpriseValue":713647808,"forwardPE":28.2,"priceToBook":0.99,"priceToSales":1.68,"enterpriseToRevenue":1.59,"enterpriseToEbitda":14.45,"pegRatio":0,"ebitda":49400000,"ebitdaMargin":11,"freeCashflow":20386500,"operatingCashflow":68957000,"totalDebt":77911000,"debtToEquity":10.2,"currentRatio":2.39,"returnOnAssets":-0.1,"returnOnEquity":-0.7,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":8.28,"targetHighPrice":11,"targetLowPrice":6.15,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":46.3,"institutionHeldPercent":19.8,"sharesOutstanding":98055952,"floatShares":60052162,"sharesShort":1957636,"shortRatio":19.7,"shortPercentOfFloat":2,"epsTrailing":-0.05,"epsForward":0.27,"revenuePerShare":4.52,"bookValue":7.74,"officers":[{"age":56,"name":"Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A.","title":"Executive Chairman"},{"age":57,"name":"Ms. Samira  Sakhia BCom, CA, CPA, MBA","title":"President, CEO & Director"},{"age":null,"name":"Mr. Arvind  Utchanah","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Leopoldo  Bosano","title":"Vice-President of Manufacturing & Operations"},{"age":null,"name":"Mr. Henrique  Dias","title":"Global Vice President of Marketing"},{"age":null,"name":"Ms. Amal  Khouri B.Sc., M.B.A.","title":"Chief Business Officer"},{"age":null,"name":"Ms. Monica  Percario","title":"Global Vice President of Regulatory & Quality"},{"age":null,"name":"Ms. Susan Caroline Emblem","title":"Global Vice President of Human Resources"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.knighttx.com","phone":"514-484-4483"}}